In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More companies sign up to open innovation

This article was originally published in Scrip

Executive Summary

Last week, Virttu Biologics, a clinical-stage biotechnology company based in Scotland, launched a new R&D network for the development of novel oncology combination therapies. The company focuses on new treatments based on oncolytic viruses, and the new Virttu Replicate Open Innovation Forum, which is open to researchers in academia as well as in biopharmaceutical companies, is intended to stimulate the development of new combination therapies by providing access to Virttu’s Seprehvir oncolytic virus.

Advertisement
Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC019440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel